BVAXF (BioVaxys Technology) OCF Margin %: 0.00% (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology OCF Margin %?

BioVaxys Technology BVAXF OCF Margin % is 0.00% as of Jul. 2025. Among 957 Biotechnology companies, BioVaxys Technology ranks worse than 104493.1% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BioVaxys Technology's Cash Flow from Operations for the three months ended in Jul. 2025 was $-0.77 Mil. BioVaxys Technology's Revenue for the three months ended in Jul. 2025 was $0.00 Mil. Therefore, BioVaxys Technology's OCF Margin % for the quarter that ended in Jul. 2025 was 0.00%.

As of today, BioVaxys Technology's current OCF Yield % is -58.87%.

The historical rank and industry rank for BioVaxys Technology's OCF Margin % or its related term are showing as below:


BVAXF's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -67.62
* Ranked among companies with meaningful OCF Margin % only.

BioVaxys Technology OCF Margin % Related Terms

BioVaxys Technology OCF Margin % Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology OCF Margin % Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BioVaxys Technology's OCF Margin for the fiscal year that ended in Oct. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Oct. 2024 )/Revenue (A: Oct. 2024 )
=-1.353/0
= %

BioVaxys Technology's OCF Margin for the quarter that ended in Jul. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jul. 2025 )/Revenue (Q: Jul. 2025 )
=-0.772/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
BioVaxys Technology (BVAXF) has a OCF Margin % of 0.00% as of Jul. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioVaxys Technology and its competitors. According to the industry distribution chart, BioVaxys Technology ranks #999999 out of 957 companies in the Biotechnology industry.
Is BioVaxys Technology's OCF Margin % too high?
BioVaxys Technology's current OCF Margin % is 0.00%. Based on the distribution chart, BioVaxys Technology ranks #999999 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does BioVaxys Technology's OCF Margin % compare to BPTH and AZTR?
According to the Biotechnology industry distribution chart, BioVaxys Technology ranks #999999 out of 957 companies for OCF Margin %. This places BioVaxys Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioVaxys Technology and its competitors. BioVaxys Technology's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (BVAXF) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BioVaxys Technology (BVAXF), the current OCF Margin % is 0.00% as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges 5LB0:GermanyBIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.